Mechanisms of leucocyte migration inhibition by breast tumour cell fractions

Abstract

Summary.-Leucocyte migration inhibition by autologous breast tumour cell fractions was mediated by a soluble factor synthesized and released by mononuclear leucocytes and active against migrating granulocytes. This mechanism is similar to that previously described in respect to cell-mediated sensitivity to microbial antigens. Alternative mechanisms involving directly reactive granulocytes or cytophilic antibodies were rarely operative in the migration tests.

Specific and aspecific immune responsiveness in lung cancer patients: Cutaneous delayed hypersensitivity reactions to a lung cancer‐associated antigen

“…These oncofetal antigens were identified by a specific heteroantiserum system and were readily used with success for immunodiagnosis, once very sensitive and specific procedures, such as radioimmunoassay (RIA) had been set up [Thomson et al, 19691. The immunogenicity of tumor-associated antigens was demonstrated in humans by eliciting delayed hypersensitivity reactions to cancer cells, cellular and tissue extracts, and autologous-and allogeneic-specific antigens of malignant tumors in cancer patients [Vanky et al, 1974;Mavligit et al, 1973;Herberman, 19741. Cell-mediated immune response was evaluated by different immunological assays in vivo and in vitro (skin testing, migration inhibition procedure, leukocyte-migration technique, mixed lymphocyte-tumor interaction) in breast cancer [Alford et al, 1973;Andersen et al, 1970;Stewart et al, 1971;Black et al, 1974;Hollinshead et al, 1974b;Jones, 1976;McCoy et al, 19761, in gastrointestinal cancer [Hollinshead et al, , 1972Herberman et al, 19711, in melanoma [Gorodilova et al, 1969;Hollinshead et al, 1974a;Char et al, 1974;Herberman et al, 1975;Cochran et al, 19731, and in bronchogenic cancer [Wells et al, 1973;Hollinshead et al, 1974c;Rees, 1975;Oldham et al, 1976;Boddie et al, 19741. A lung cancer-associated antigen (LCAA) was separated and identified in our laboratory by a specific heteroantiserum from surgery specimens.…”